Dr. Lee on Defining Smoldering Multiple Myeloma

Video

In Partnership With:

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Sarah S. Lee, MD, physician, Seattle Cancer Care Alliance, assistant professor, Division of Medical Oncology, University of Washington School of Medicine, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses definition criteria for smoldering multiple myeloma.

Laboratory findings, as well as bone marrow biopsy results, are used to make a diagnosis of smoldering multiple myeloma, Lee explains. The International Myeloma Working (IMW) Group recommends that all patients with suspected smoldering multiple myeloma undergo a PET-CT scan, a low-dose whole body CT scan, or an MRI of the whole body or spine.

Per the IMW Group criteria, patients with smoldering myeloma must have a serum monoclonal protein of at least 30 g/L or a urinary monoclonal protein of at least 500 mg/day and/or clonal bone marrow plasma cells of 10% to 60%, Lee says.

Additionally, patients must not have any myeloma-defining events or amyloidosis, Lee concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute